Development of covalent antagonists for β1- and β2-adrenergic receptors.
Development of covalent antagonists for β1- and β2-adrenergic receptors.
复制标题
β1-和β2-肾上腺素能受体共价拮抗剂的开发
DOI:
10.1016/j.bmc.2019.05.034
复制
发表时间:
2019
影响因子:
3.5
通讯作者:
P. Gmeiner
中科院分区:
文献类型:
--
作者:
T. Schwalbe;H. Hübner;P. Gmeiner
The selective covalent tethering of ligands to a specific GPCR binding site has attracted considerable interest in structural biology, molecular pharmacology and drug design. We recently reported on a covalently binding noradrenaline analog (FAUC37) facilitating crystallization of the β2-adrenergic receptor (β2ARH2.64C) in an active state. We herein present the stereospecific synthesis of covalently binding disulfide ligands based on the pharmacophores of adrenergic β1- and β2receptor antagonists. Radioligand depletion experiments revealed that the disulfide-functionalized ligands were able to rapidly form a covalent bond with a specific cysteine residue of the receptor mutants β1ARI2.64Cand β2ARH2.64C. The propranolol derivative (S)-1ainduced nearly complete irreversible blockage of the β2ARH2.64Cwithin 30 min incubation. The CGP20712A-based ligand(S)-4showed efficient covalent blocking of the β2ARH2.64Cat very low concentrations. The analog(S)-5arevealed extraordinary covalent cross-linking at the β1ARI2.64Cand β2ARH2.64Cmutant while retaining a 41-fold selectivity for the β1AR wild type over β2AR. These compounds may serve as valuable molecular tools for studying β1/β2subtype selectivity or investigations on GPCR trafficking and dimerization.
登录
查看更多内容
影响因子:
1.9
作者:
Wachter, S. Blake;Gilbert, Edward M.
通讯作者:
Gilbert, Edward M.
DOI:
10.1146/annurev.pa.25.040185.001205
发表时间:
1985
影响因子:
12.5
作者:
A. Takemori;P. Portoghese
通讯作者:
A. Takemori;P. Portoghese
影响因子:
5
作者:
S. Louis;T. Nero;D. Iakovidis;G. Jackman;W. Louis
通讯作者:
W. Louis
影响因子:
3
作者:
A. Wellstein;D. Palm;Belz Gg
通讯作者:
Belz Gg
影响因子:
7.3
作者:
W. Fuhrer;F. Ostermayer;M. Zimmermann;M. Meier;H. Müller
通讯作者:
H. Müller